Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1654 1671 1675
This examiner grants 76% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18734979 | ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18252800 | MODIFIED SECRETED HEPATITIS C VIRUS (HCV) E1E2 GLYCOPROTEINS AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18050806 | THERAPEUTIC AND PREVENTATIVE CANCER VACCINES | Non-Final OA | Arizona Board of Regents on Behalf of Arizona State University |
| 17819259 | DRY POWDER COMPOSITIONS OF OIL-IN-WATER (O/W) EMULSION ADJUVANTED VACCINES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17747358 | MULTIGENIC MVA-SARS-COV-2 VACCINE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18188527 | ONE-POT PATHOGEN DETECTION SYSTEM AND METHOD FOR REAL-TIME LATERAL FLOW ASSAY | Non-Final OA | City University of Hong Kong |
| 17749716 | ASSAYS FOR VIRAL STRAIN DETERMINATION | Final Rejection | Meso Scale Technologies, LLC. |
| 18313158 | ADENO-ASSOCIATED VIRUS VECTORS | Non-Final OA | The Children's Medical Center Corporation |
| 18621631 | CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES | Final Rejection | VERIMMUNE INC. |
| 18037022 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | Non-Final OA | CHA VACCINE RESEARCH INSTITUTE CO., LTD |
| 18407958 | Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 17618283 | MUCOSAL VACCINE FORMULATIONS | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 17786631 | Nucleic acid vaccination using neo-epitope encoding constructs | Non-Final OA | Evaxion Biotech A/S |
| 17761371 | AN ANAPLASTIC LYMPHOMA KINASE (ALK) CANCER VACCINE AND METHODS OF USE | Non-Final OA | Children's Medical Center Corporation |
| 18461321 | RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED HA FOR REPLICATION IN EGGS | Final Rejection | Wisconsin Alumni Research Foundation (WARF) |
| 17283658 | RECOMBINANT RSV LIVE VACCINE STRAIN AND PRODUCTION METHOD THEREFOR | Non-Final OA | SK BIOSCIENCE CO., LTD. |
| 17612179 | Yeast-Based Oral Vaccination | Final Rejection | ESPEROVAX INC. |
| 18252790 | DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES | Non-Final OA | Greffex, Inc. |
| 18026404 | NOVEL AGONIST VACCINE FORMULATION | Non-Final OA | BHARAT BIOTECH INTERNATIONAL LIMITED |
| 18022428 | ASSAY FOR SARS-CoV-2 INFECTION OF VULNERABLE HUMAN CELLS | Non-Final OA | The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads |
| 17996300 | INFLUENZA VIRUS-LIKE PARTICLES (VLPS) | Final Rejection | ÖSTERREICHISCHE AGENTUR FÜR GESUNDHEIT UND ERNÄHRUNGSSICHERHEIT GMBH |
| 17932320 | NON-NEUROINVASIVE VIRUSES AND USES THEREOF | Non-Final OA | TRUSTEES OF TUFTS COLLEGE (AKA TUFTS UNIVERSITY) |
| 17288656 | HYALURONIC ACID AS A NATURAL ADJUVANT FOR PROTEIN AND PEPTIDE-BASED VACCINES | Non-Final OA | ISTITUTO ONCOLOGICO VENETO IOV-IRCCS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy